PORTEFEUILLE

ZuriEV is developing a next-generation liquid biopsy platform that enables early and accurate cancer detection from a simple blood draw. This overcomes challenges associated with current standard technologies, such as tissue biopsies and imaging. Our solution is based on small particles, known as extracellular vesicles, which are secreted from all cells in the body into circulation and carry all information from the cell of origin. We developed proprietary biomarkers that enable a quantitative detection of cancer cell-derived extracellular vesicles and also their isolation for downstream analyses on a DNA, RNA and protein level. This innovation offers a breakthrough in sensitivity and clinical accessibility. With expected applications in diagnostics and monitoring, ZuriEV has the potential to improve patient outcomes and reduce healthcare costs worldwide significantly.

ZuriEV has successfully completed proof-of-concept studies on over 1,000 blood samples, demonstrating high diagnostic accuracy for blood-based detection of cancer, including those that have been previously difficult to detect, such as brain cancer. We are currently developing a prototype diagnostic kit and testing service and aim for the regulatory path towards a CE mark. The project closes a major gap in non-invasive early cancer detection, especially for brain tumors, where no reliable blood-based tests exist. We plan a spin-off company from the University of Zurich, strategic partnerships with clinical centers and diagnostics industry stakeholders. We’ve secured significant non-dilutive funding and are preparing for a seed round. Implementation activities include pilot user evaluations, regulatory alignment, and market access planning across Switzerland, the EU, and the US.